Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Peptide Regulatory Landscape
The peptide regulatory landscape shifted significantly in early 2026. Following HHS Secretary Robert F. Kennedy Jr.'s February 27, 2026 announcement, approximately 14 of the 19 peptides previously placed on the FDA's Category 2 restricted list are being returned to Category 1, restoring legal compounding access through licensed pharmacies with a clinician's prescription. The FDA continues to refine its approach to compounded peptides under the FD&C Act, and state boards of pharmacy and medicine continue to issue their own guidance. Providers must stay current on federal rules, the 503A/503B framework, and state-specific restrictions to maintain compliant practices.
Last updated: September 11, 2026
Active Regulatory Alerts
Mounjaro's Label Expands; Type 1 Diabetes on the Rise; Testosterone and Afib
The FDA has expanded the approved indication for tirzepatide (Mounjaro) to include reduction of major adverse cardiovascular events in high-risk adults with type 2 diabetes, a significant label update announced by Eli Lilly. This expanded cardiovascular indication reinforces tirzepatide's growing clinical profile beyond glycemic control and weight management. The development is expected to broaden prescribing patterns and further drive market growth for the dual GLP-1 and GIP receptor agonist.
Source: MedPage Today
Read moreMounjaro scores FDA approval to reduce CV risk; Teva to buy an approved drug
The FDA has approved Eli Lilly's tirzepatide (Mounjaro) for the reduction of major adverse cardiovascular events, marking a significant expansion of the GLP-1/GIP receptor agonist's approved indications beyond glycemic control and weight management. This approval strengthens tirzepatide's clinical profile and reinforces the cardiovascular benefit class established by GLP-1 receptor agonists. The decision is expected to have broad implications for prescribing patterns, payer coverage, and the competitive landscape among incretin-based therapies.
Source: Endpoints News
Read moreImpacts of CMS' GLP-1 pilot program begin to take shape
A federal CMS pilot program expanding access to GLP-1 weight loss medications for Medicare-eligible seniors is yielding early uptake data and reported patient benefits nearly two months after launch. The findings offer an initial look at how government-sponsored coverage of GLP-1 receptor agonists may reshape prescribing patterns and access among older populations. Analysts and providers are watching closely as the program's outcomes could influence broader Medicare drug coverage policy for this class of therapeutics.
Source: Endpoints News
Read moreWatchdog Urges HHS to Investigate Conflicts Among FDA's Peptide Panelists
A consumer watchdog group has formally requested that the HHS Office of Inspector General investigate potential conflicts of interest among members of an FDA advisory committee that recommended adding six peptides to the agency's list of restricted compounds. The demand raises significant questions about the integrity of the advisory process that directly shapes which peptides remain accessible through compounding pharmacies. The outcome of this inquiry could have substantial regulatory implications for providers and patients who rely on compounded peptide therapies.
Source: MedPage Today
Read moreEli Lilly files first lawsuits over retatrutide 'black market'
Eli Lilly has initiated legal action against six U.S. companies accused of illegally selling unauthorized versions of retatrutide, the company's investigational GIP, GLP-1, and glucagon receptor triple agonist still in clinical trials. The lawsuits mark the first enforcement litigation by Lilly targeting the illicit compounding and distribution of this pipeline obesity and diabetes drug. The case highlights growing pharmaceutical industry efforts to combat unauthorized peptide sales ahead of potential FDA approval.
Source: Endpoints News
Read moreWhat would it take to get peptides on the shelf?
An FDA advisory panel's recent vote to green-light select popular peptides has drawn significant attention to the consumer peptide market and raised substantive questions about regulatory pathways for these compounds. The NPR report examines what formal FDA oversight would mean for product safety, supply chain integrity, and access for patients currently relying on compounding pharmacies or unregulated sources. The decision marks a potentially pivotal moment in how peptide therapies are classified, distributed, and monitored in the United States.
Source: NPR Health
Read moreThe Double Standard in the Peptide Vote
A MedPage Today opinion piece challenges the recent federal advisory committee recommendation on peptides, questioning whether the scrutiny applied meets the standards ordinarily required for prescribing regulated compounds. The author argues that fundamental questions about molecular identity, dosing, and clinical basis are being bypassed in the committee's approach. The piece raises important concerns for prescribing clinicians navigating the evolving regulatory landscape around peptide therapeutics.
Source: MedPage Today
Read moreFDA offers updated guidance for generics of weight loss blockbusters
The FDA has issued revised draft guidance for generic drug developers seeking to create copycat versions of leading GLP-1 and GIP receptor agonist therapies, including semaglutide and tirzepatide. The updated guidance addresses bioequivalence and formulation standards that generic manufacturers must meet, signaling a significant regulatory step toward broader market competition for these blockbuster compounds. This development carries direct implications for compounding pharmacies and the broader GLP-1 prescribing landscape.
Source: Endpoints News
Read moreA trend that isn't fading, ultra-processed baby foods
A recent FDA advisory panel session included discussion of several peptide-related regulatory matters alongside broader public health topics covered in STAT News Morning Rounds. The brief reference to peptide developments signals continued federal attention to the regulatory status of peptide compounds in clinical and commercial contexts.
Source: STAT News
Read moreThe future of gray-market peptides
An FDA advisory committee convened a two-day review to deliberate whether compounding pharmacies should retain the ability to produce seven specific peptides, a decision with sweeping implications for the compounding industry and patient access. The debate highlights ongoing regulatory tension between pharmaceutical manufacturers and compounding pharmacies over the legal status of peptide compounds. The outcome of this advisory process is expected to shape the future availability of widely used compounded peptide therapies.
Source: Endpoints News
Read moreHHS Reclassifies 14 Peptides From Category 2 Back to Category 1
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides previously placed on the FDA's Category 2 restricted list will be moved back to Category 1. Affected peptides include BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, Selank, and Semax. Licensed 503A compounding pharmacies may once again prepare these peptides pursuant to a valid clinician prescription. Reclassification does NOT mean the peptides are FDA-approved drugs, the 503A framework, documentation, and medical-necessity requirements still apply.
Source: HHS / FDA
FDA Clarifies Compounded GLP-1 Policy and 'Essentially a Copy' Standard
On April 1, 2026, the FDA issued clarifying guidance reminding 503A pharmacies and 503B outsourcing facilities that compounded drugs qualify for the FD&C Act statutory exemptions only when applicable conditions are satisfied, with specific focus on the 'essentially a copy' standard. Because the tirzepatide shortage was resolved in December 2024 and the semaglutide shortage in February 2025, compounders preparing GLP-1 analogues must document clinical-difference justification for each patient and should review their 'essentially a copy' analysis.
Source: FDA.gov
GLP-1 Shortages Resolved: Wind-Down Period Enforcement
The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025. Compounding under shortage provisions has ended, and phased enforcement grace periods have expired. 503A pharmacies may continue patient-specific compounding only where a documented clinical difference justifies it (not as an essential copy of the commercial product). Providers should verify each prescription meets the 'essentially a copy' standard.
Source: FDA Drug Shortage Database
DEA Scheduling Considerations for Peptide Practices
While most therapeutic peptides are not scheduled substances, providers should be aware that certain peptide hormones (e.g., synthetic growth hormone analogues) may trigger DEA scrutiny depending on intended use. Maintain thorough documentation of medical necessity for all peptide prescriptions.
Source: DEA Diversion Control
Join Our Community
Connect with patients, health enthusiasts, and providers discussing peptide therapy, regulatory updates, and the latest research.
Join the CommunityLegal Disclaimer
This page is for educational and informational purposes only and does not constitute legal or regulatory advice. Regulatory requirements change frequently. Providers should consult with qualified legal counsel and verify current regulations with the FDA, their state board of medicine, and state board of pharmacy before making compliance decisions.